Abstract
Glucagon-like peptide-1 (GLP-1)-based therapy is a novel treatment for type 2 diabetes. It is executed either by GLP-1 mimetics or by dipeptidyl peptidase-IV inhibitors. In type 2 diabetes, the two strategies reduce hemoglobin A(1c) by 0.6% to 1.1% from baseline levels of 7.7% to 8.5%. They are efficient both in monotherapy and in combination with metformin or thiazolidinediones. Both treatments are well tolerated with low risk of hypoglycemia.
| Original language | English |
|---|---|
| Pages (from-to) | 340-347 |
| Journal | Current Diabetes Reports |
| Volume | 7 |
| Issue number | 5 |
| Publication status | Published - 2007 |
Subject classification (UKÄ)
- Endocrinology and Diabetes
